The DOI matches its Crossref record; 168 of the 176 references it cites were found in a registry or an index.
Can herbs provide a new generation of drugs for treating Alzheimer’s disease?
Abstract
The overall aim of this review is to discuss cellular mechanisms at work in the progression of AD and current therapeutic strategies for treating AD, with a focus on the potential efficacy of herbal treatments. Recent advances in molecular, cellular, and animal model studies have revealed that formation of the 4-kDa amyloid beta peptide is a key factor in the development and progression of AD. Several cellular changes have been identified that are related to amyloid beta plaques and neurofibrillary tangles found in the autopsied brains of AD patients and in AD animal models. Several therapeutic strategies have been developed to treat AD, including anti-inflammatory, anti-oxidant, and anti-amyloid approaches. Recently, herbal treatments have been tested in animal and cellular models of AD and in clinical trials with AD subjects. In AD animal models and cell models, herbal extracts appear to have fewer adverse effects than beneficial effects on A beta and cognitive functions. These extracts have multi-functional properties (pro-cholinergic, anti-oxidant, anti-amyloid, and anti-inflammatory), and their use in the treatment of AD patients looks promising. The chemical compositions of herbs and their potential for alleviating or reducing symptoms of AD or for affecting the disease mechanism need to be further studied.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The worldwide increasing tendency toward using phytochemicals may be due to low toxicity, and synergistic effects [199,200,201].”
From Multi-Target Mechanisms of Phytochemicals in Alzheimer’s Disease: Effects on Oxidative Stress, Neuroinflammation and Protein Aggregation (2022) · cites this paper as [199]
Citations
Cites
Alzheimer's Disease: Genes, Proteins, and Therapy
Selkoe, D. J. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.741 · Cited by 6,063
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420
Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies
Manach, C., Williamson, G., Morand, C., Scalbert, A., & Rémésy, C. (2005) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/81.1.230s · Cited by 4,219
Triple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles
Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., & LaFerla, F. M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00434-3 · Cited by 4,126
Flavonoids: a review of probable mechanisms of action and potential applications.
Nijveldt, R., van Nood, E., van Hoorn, D. V., Boelens, P., van Norren, K., & van Leeuwen, P. V. (2001) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/74.4.418 · Cited by 3,232
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
Pathways towards and Away from Alzheimer’s Disease
Mattson, M. P. (2004) · Nature · doi:10.1038/nature02621 · Cited by 3,052
Oxidative stress hypothesis in Alzheimer’s disease
Markesbery, W. R. (1997) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(96)00629-6 · Cited by 2,383
Yang, F., Lim, G. P., Begum, A. N., Ubeda, O. J., Simmons, M. R., Ambegaokar, S. S., Chen, P. P., Kayed, R., Glabe, C. G., Frautschy, S. A., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m404751200 · Cited by 2,336
Flavonoids: antioxidants or signalling molecules?
Williams, R. J., Spencer, J. P. E., & Rice-Evans, C. (2004) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2004.01.001 · Cited by 2,016
Research works printed but not linked: 1
- Reddy, 2005, Mapping cellular transcriptosomes in autopsied Alzheimer's disease subjects and relevant mouse models, Neurobiol. Aging.
Cited by
Sorted by citations
Resveratrol—A boon for treating Alzheimer's disease?
Anekonda, T. S. (2006) · Brain Research Reviews · doi:10.1016/j.brainresrev.2006.04.004 · Cited by 343
“The enormous diversity of functions in natural compounds, such as resveratrol and other herbs, may provide a new generation of drugs for treating AD patients (Anekonda and Reddy, 2005; Bastianetto and Quirion, 2004; Howes and Houghton, 2003; Howes et al., 2003).”
BackgroundPlants traditionally used in age related brain disorders—A survey of ethnobotanical literature
Adams, M. A., Gmünder, F., & Hamburger, M. O. (2007) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2007.07.016 · Cited by 328
Mitochondria as a Therapeutic Target for Aging and Neurodegenerative Diseases
Reddy, P. H., & Reddy, T. P. (2011) · Current Alzheimer Research · doi:10.2174/156720511795745401 · Cited by 233
Limpeanchob, N., Jaipan, S., Rattanakaruna, S., Phrompittayarat, W., & Ingkaninan, K. (2008) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2008.07.039 · Cited by 206
Metabolic syndrome and the role of dietary lifestyles in Alzheimer’s disease
Pasinetti, G. M., & Eberstein, J. A. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05454.x · Cited by 160
Metadata
- Authors
- Anekonda, T. S., & Reddy, P. H.
- Affiliations
- Oregon Health & Science University (US)
- Corresponding author
- Reddy, P. Hemachandra
- Venue
- Brain Research Reviews
- Publisher
- Elsevier BV
- Published
- 2005-12
- Volume
- 50
- Issue
- 2
- Pages
- 361-376
- ISSN
- 0165-0173 (ISSN-L)
- OpenAlex
- W1991124307
- Cited by
- 140
- References
- 176
- Citations by year
- 2026: 1 · 2024: 3 · 2023: 3 · 2022: 3 · 2021: 5 · 2020: 11 · 2019: 12 · 2018: 8 · 2017: 6 · 2016: 9 · 2015: 8 · 2014: 10 · 2013: 10 · 2012: 6
- FWCI
- 0.75
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Brain Research Reviews (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (1r03ag022643-01)
- National Institute on Aging (AG 22643)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Complementary and alternative medicine › Medicinal Plants and Neuroprotection
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, herbal medicine, amyloid-beta, amyloid plaques, neurofibrillary tangles, anti-amyloid therapy, anti-inflammatory therapy, antioxidant therapy, cognitive function, plant extracts, animal models of Alzheimer's disease
- MeSH terms
- Alzheimer Disease, Animals, Antioxidants, Disease Models, Animal, Humans, Plant Extracts, Herbal Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
